138 related articles for article (PubMed ID: 25739357)
41. Purinoceptors in renal microvessels: adenosine-activated and cytochrome P450 monooxygenase-derived arachidonate metabolites.
Carroll MA; Cheng MK; Liclican EL; Li J; Doumad AB; McGiff JC
Pharmacol Rep; 2005; 57 Suppl():191-5. PubMed ID: 16415499
[TBL] [Abstract][Full Text] [Related]
42. Regulation of adenosine A
Micioni Di Bonaventura MV; Pucci M; Giusepponi ME; Romano A; Lambertucci C; Volpini R; Micioni Di Bonaventura E; Gaetani S; Maccarrone M; D'Addario C; Cifani C
J Psychopharmacol; 2019 Dec; 33(12):1550-1561. PubMed ID: 31161847
[TBL] [Abstract][Full Text] [Related]
43. Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γ Agonists/Soluble Epoxide Hydrolase Inhibitors.
Lillich FF; Willems S; Ni X; Kilu W; Borkowsky C; Brodsky M; Kramer JS; Brunst S; Hernandez-Olmos V; Heering J; Schierle S; Kestner RI; Mayser FM; Helmstädter M; Göbel T; Weizel L; Namgaladze D; Kaiser A; Steinhilber D; Pfeilschifter W; Kahnt AS; Proschak A; Chaikuad A; Knapp S; Merk D; Proschak E
J Med Chem; 2021 Dec; 64(23):17259-17276. PubMed ID: 34818007
[TBL] [Abstract][Full Text] [Related]
44. Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator.
Hartmann M; Bibli SI; Tews D; Ni X; Kircher T; Kramer JS; Kilu W; Heering J; Hernandez-Olmos V; Weizel L; Scriba GKE; Krait S; Knapp S; Chaikuad A; Merk D; Fleming I; Fischer-Posovszky P; Proschak E
J Med Chem; 2021 Mar; 64(5):2815-2828. PubMed ID: 33620196
[TBL] [Abstract][Full Text] [Related]
45. Adenosine Receptor A1-A2a Heteromers Regulate EAAT2 Expression and Glutamate Uptake via YY1-Induced Repression of PPAR
Hou X; Li Y; Huang Y; Zhao H; Gui L
PPAR Res; 2020; 2020():2410264. PubMed ID: 32206061
[TBL] [Abstract][Full Text] [Related]
46. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor.
Milne GR; Palmer TM
ScientificWorldJournal; 2011 Feb; 11():320-39. PubMed ID: 21298223
[TBL] [Abstract][Full Text] [Related]
47. G protein β
McIntire WE; Purdy MD; Leonhardt SA; Kucharska I; Hanson MA; Poulos S; Garrison JC; Linden J; Yeager M
Res Sq; 2024 Jan; ():. PubMed ID: 38343806
[TBL] [Abstract][Full Text] [Related]
48. Drug Delivery and Nanoformulations for the Cardiovascular System.
Geldenhuys WJ; Khayat MT; Yun J; Nayeem MA
Res Rev Drug Deliv; 2017 Feb; 1(1):32-40. PubMed ID: 28713881
[TBL] [Abstract][Full Text] [Related]
49. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
[TBL] [Abstract][Full Text] [Related]
50. The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.
Kodani SD; Hammock BD
Drug Metab Dispos; 2015 May; 43(5):788-802. PubMed ID: 25762541
[TBL] [Abstract][Full Text] [Related]
51. The metabolism of lysophosphatidic acids by allelic variants of human soluble epoxide hydrolase.
Purba ER; Leuhery EA; Oguro A; Imaoka S
Drug Metab Pharmacokinet; 2015 Feb; 30(1):75-81. PubMed ID: 25760533
[TBL] [Abstract][Full Text] [Related]
52. Contribution of epoxyeicosatrienoic acids to the cerebral blood flow response to hypoxemia.
Liu X; Gebremedhin D; Harder DR; Koehler RC
J Appl Physiol (1985); 2015 Nov; 119(10):1202-9. PubMed ID: 25792716
[TBL] [Abstract][Full Text] [Related]
53. Dysregulation of soluble epoxide hydrolase and lipidomic profiles in anorexia nervosa.
Shih PB; Yang J; Morisseau C; German JB; Zeeland AA; Armando AM; Quehenberger O; Bergen AW; Magistretti P; Berrettini W; Halmi KA; Schork N; Hammock BD; Kaye W
Mol Psychiatry; 2016 Apr; 21(4):537-46. PubMed ID: 25824304
[TBL] [Abstract][Full Text] [Related]
54. TRPV4 Is Required for Hypoxic Pulmonary Vasoconstriction.
Goldenberg NM; Wang L; Ranke H; Liedtke W; Tabuchi A; Kuebler WM
Anesthesiology; 2015 Jun; 122(6):1338-48. PubMed ID: 25815455
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of Human Soluble Epoxide Hydrolase Exacerbates Coronary Reactive Hyperemia Reduction in Angiotensin-II-Treated Mouse Hearts.
Hanif A; Edin ML; Zeldin DC; Nayeem MA
J Cardiovasc Pharmacol; 2024 Jan; 83(1):46-54. PubMed ID: 37788350
[TBL] [Abstract][Full Text] [Related]
56. Soluble Epoxide Hydrolase Inhibition by
Overby H; Yang Y; Xu X; Graham K; Hildreth K; Choi S; Wan D; Morisseau C; Zeldin DC; Hammock BD; Wang S; Bettaieb A; Zhao L
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987880
[TBL] [Abstract][Full Text] [Related]
57.
Agba S; Hanif A; Edin ML; Zeldin DC; Nayeem MA
Front Pharmacol; 2020; 11():27. PubMed ID: 32116704
[TBL] [Abstract][Full Text] [Related]
58. Ephx2-gene deletion affects acetylcholine-induced relaxation in angiotensin-II infused mice: role of nitric oxide and CYP-epoxygenases.
Hanif A; Edin ML; Zeldin DC; Nayeem MA
Mol Cell Biochem; 2020 Feb; 465(1-2):37-51. PubMed ID: 31797255
[TBL] [Abstract][Full Text] [Related]
59. Adenosine and the Cardiovascular System.
Reiss AB; Grossfeld D; Kasselman LJ; Renna HA; Vernice NA; Drewes W; Konig J; Carsons SE; DeLeon J
Am J Cardiovasc Drugs; 2019 Oct; 19(5):449-464. PubMed ID: 30972618
[TBL] [Abstract][Full Text] [Related]
60. Enhanced A
Yadav VR; Teng B; Mustafa SJ
Eur J Pharmacol; 2019 Jan; 842():111-117. PubMed ID: 30347181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
